Over the last two decades, nanoparticulate delivery systems have revolutionized cancer
treatment by achieving target-specific delivery, enhanced bioavailability, and improved …

Retinoblastoma is the most common intraocular malignancy in children. The treatment of this
rare disease is still challenging in developing countries due to delayed diagnosis. The …

Introduction Retinal disease affects millions of people worldwide, generating a massive
social and economic burden. Current clinical trials for retinal diseases are dominated by …

Background Retinoblastoma (RB) is a rare type of pediatric ocular cancer with difficulty in
treatment and detection owing to alterations in tumor suppressor genes and the lack of …

Nano-delivery systems have significantly evolved over the last decade for the treatment of
cancer by enabling site-specific delivery and improved bioavailability. The widely …

For patients with hereditary retinal diseases, retinal gene therapy offers significant promise
for the prevention of retinal degeneration. While adeno-associated virus (AAV)-based …

Over the last few years, huge progress has been made in the understanding of molecular
mechanisms underlying the pathogenesis of retinal degenerative diseases. Such …

While the systemic route of administration enables therapeutic genes to spread through the
bloodstream and access target cells, it is a challenge to achieve this. Several studies …

Nanotherapeutics has the potential of providing limitless opportunities in the area of drug
and gene delivery for treatment of cancer. Although the path toward commercialization of …

Nanoparticles (NPs) have been widely applied for drug delivery. NPs circumvent many
challenges of the traditional drug. They improve the drug biosafety, enhance the drug …